Skip to main content
PMC home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2014 Dec 4;5(12):e1548. doi: 10.1038/cddis.2014.497

Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells

G Castoria 1,*,4, P Giovannelli 1,4, M Di Donato 1, A Ciociola 1, R Hayashi 2, F Bernal 3, E Appella 2, F Auricchio 1, A Migliaccio 1,*
PMCID: PMC4649827  PMID: 25476896

Abstract

The functions of androgen receptor (AR) in stromal cells are still debated in spite of the demonstrated importance of these cells in organ development and diseases. Here, we show that physiological androgen concentration (10 nM R1881 or DHT) fails to induce DNA synthesis, while it consistently stimulates cell migration in mesenchymal and transformed mesenchymal cells. Ten nanomolar R1881 triggers p27 Ser10 phosphorylation and its stabilization in NIH3T3 fibroblasts. Activation of Rac and its downstream effector DYRK 1B is responsible for p27 Ser10 phosphorylation and cell quiescence. Ten nanomolar androgen also inhibits transformation induced by oncogenic Ras in NIH3T3 fibroblasts. Overexpression of an AR mutant unable to interact with filamin A, use of a small peptide displacing AR/filamin A interaction, and filamin A knockdown indicate that the androgen-triggered AR/filamin A complex regulates the pathway leading to p27 Ser10 phosphorylation and cell cycle arrest. As the AR/filamin A complex is also responsible for migration stimulated by 10 nM androgen, our report shows that the androgen-triggered AR/filamin A complex controls, through Rac 1, the decision of cells to halt cell cycle and migration. This study reveals a new and unexpected role of androgen/AR signalling in coordinating stromal cell functions.

Androgens stimulate the growth of target cells, but under certain conditions slow down proliferation depending on cell type and microenvironment.1 Androgen binding to the androgen receptor (AR) induces differentiation of normal prostate epithelial cells and proliferation of transformed prostate epithelial cells.2 Additionally, AR-expressing human prostate stromal cells do not respond to androgens with proliferation.3, 4

Mesenchymal and transformed mesenchymal cells harbor a transcriptionally incompetent AR, and their proliferation is insensitive to physiological androgen concentration (10 nM R1881 or di-hydro-testosterone (DHT)).5, 6 At this concentration, these cells undergo migration as a consequence of association between AR and filamin A (FlnA).6 Androgen behaviors (proliferation/migration dichotomy) mimic those of growth factors (EGF, VEGF and PDGF), which trigger motility or proliferation depending on cell type, receptor distribution, ligand concentration and dynamic regulation of signalling networks.7, 8, 9, 10, 11, 12 The molecular basis of a cell's decision to ‘go or grow' in response to the same stimulus is not, however, completely understood.

In this study, we analyzed in NIH3T3 cells the dichotomous (proliferative/migratory) functions of AR and identified the AR/FlnA complex as the upstream player of the non-proliferative, migratory phenotype. Androgen/AR signalling initiated by the AR/FlnA complex activates Rac1, which results in cell quiescence through DYRK 1B action. Stimulation of mesenchymal cell proliferation by androgens is observed upon AR/FlnA/Rac/DYRK 1B pathway inhibition, indicating that in these cells, androgens repress the proliferative circuitry observed in classical epithelial target cells. We now report that 10 nM androgen activates the FlnA/Rac/DYRK 1B cascade to offset their growth, promoting action in mesenchymal cells. Findings in Ras-transformed fibroblasts and human fibrosarcoma HT1080 cells, harboring an activated N-Ras,13 strengthen the role of AR in lowering the proliferative potential of non-transformed or transformed mesenchymal cells, and suggest that new approaches are needed for the study and treatment of AR-related diseases.

Results

Effect of 10 nM androgens on DNA synthesis of primary, immortalized and transformed fibroblasts

NIH3T3 cells, mouse embryo fibroblasts (MEFs), primary mouse fibroblasts (MFs) and human fibrosarcoma HT1080 cells were used. In contrast to stimulation with low androgen concentration (1 picomolar; 1 pM), which has a proliferative action (Figure 1),5 challenging of NIH3T3 cells with 10 nM of the non-aromatizable agonist R1881 (Figure 1a) or 5α DHT (Figure 1c) very weakly increases BrdU incorporation in several different experiments. Stimulation of MEFs (Figure 1e), HT1080 cells (Figure 1f) or MFs (Figures 1g and h) with 10 nM R1881 or DHT does not affect DNA synthesis. Notably, the anti-androgen bicalutamide (Bic) increases BrdU incorporation, whereas it very slightly affects BrdU incorporation when added alone to the cell medium. Thus, Bic does not act on DNA synthesis by itself, but releases an inhibitory function on cell cycle progression mediated by the ligand-coupled AR. Similar results are observed using R1881 or DHT in in vitro cell growth assay in NIH3T3 cells (Figures 1b and d).

Figure 1.

Figure 1

Open in a new tab

Effect of different concentrations of androgens on DNA synthesis of mesenchymal cells. Quiescent NIH3T3 cells were used and left untreated or treated with the indicated compounds. R1881 (Perkin-Elmer) or DHT (Sigma) were used at 1 pM or 10 nM; bicalutamide (Sigma-Aldrich; Bic) was added at 1000-fold excess. In (a and c), cells on coverslips were pulsed with 100 μM BrdU and 18 h later BrdU incorporation was analyzed by IF. Data were expressed as % of cells. In (b and d), cell growth was measured 24 h later by MTT assay and data were expressed as relative increase. Quiescent mouse embryo fibroblasts (MEFs in e) or HT1080 cells (f) or primary mouse fibroblasts (MFs in g and h) on coverslips were left untreated or treated for 18 h with the indicated concentration of R1881 or DHT. Bicalutamide was added at 1000-fold excess. BrdU incorporation was analyzed as above and expressed as % of cells. In (a–h), means and S.E.M. are shown. n represents the number of experiments throughout the figures

Ten nanomolar R1881 or DHT significantly increases motility of NIH3T3 fibroblasts (Supplementary Figure 1S A), MEFs, MFs and HT1080 cells (Supplementary Figure 2S),5,6 and Bic inhibits androgen-induced migration. Thus, Bic inhibits the migratory capacity of fibroblasts, while increasing their proliferative rate.

NIH3T3 fibroblasts do not express estradiol or progesterone receptor (ER or PgR; Supplementary Figures 1S B). Consistently, neither estradiol nor the synthetic progestin R5020 affects migration (Supplementary Figures 1S A), DNA synthesis (Supplementary Figures 1S C) or in vitro growth (Supplementary Figures 1S D).

In sum, 10 nM R1881 or DHT, which induces cell cycle progression in various AR-expressing epithelial cancer cells,14 does not drive DNA synthesis in primary, immortalized and transformed fibroblasts, unless they are treated with Bic.

Ten nanomolar R1881 triggers p27 Ser10 phosphorylation and stabilization, inducing quiescence in NIH3T3 fibroblasts

p27 levels are elevated in quiescent cells and decrease upon mitogenic stimulation.15 Ten nanomolar R1881 neither downregulates p27 (Figure 2a) nor allows DNA synthesis in NIH3T3 cells (Figure 2b). In contrast, low R1881 concentration (1 pM) decreases p27 levels (Figure 2a) and increases DNA synthesis (Figure 2b). As p27 expression might be transcriptionally regulated,15 we analyzed the androgen effect on luciferase reporter construct driven by the p27 promoter. Neither 10 nM nor 1 pM R1881 modifies p27 transcription in gene reporter assay, whereas serum stimulation of quiescent NIH3T3 fibroblasts increases (about fourfold) p27 transcription (Supplementary Figures 3S A). p27 is localized in the nuclei of quiescent cells and is exported in cytoplasm as the cells progress toward S-phase.15 Consistently, p27 is detectable in the cytoplasm of cells treated with the proliferative R1881 concentration (1 pM), whereas it remains in the nuclei of 10 nM R1881-treated cells, mimicking the results observed in quiescent cells (Figure 2c and Supplementary Figure 3S B).

Figure 2.

Figure 2

Open in a new tab

Ten nanomolar R1881-triggered p27 Ser10 phosphorylation induces quiescence. Quiescent NIH3T3 cells were used. In (a), quiescent cells were untreated or treated for the indicated times with 10 nM or 1 pM R1881. Lysate proteins were analyzed using anti-p27 (p27) antibody. Filters were re-probed with the anti-tubulin (tub) Ab, as a loading control. In (b), cells on coverslips were left untreated or treated with the indicated concentration of R1881 and pulsed with BrdU. BrdU incorporation was analyzed as above and expressed as % of cells. In (c), cells on coverslips were left untreated or treated for the indicated times with R1881 (10 nM or 1 pM). p27 was stained and visualized by IF. Cells showing exclusively nuclear p27 were scored and results expressed as % of cells. Data are derived from at least 600 scored cells for each experiment. In (d), cells were untreated or treated for the indicated times with 10 nM R1881. Lysate proteins were analyzed by western blot, using antibodies against the indicated proteins. In (e), cells were transfected with the empty (ctrl) or wt p27 or S10A p27 encoding plasmids. Transfected cells on coverslips were made quiescent and then untreated or treated for 18 h with 10 nM R1881. After in vivo pulse, BrdU incorporation was analyzed and expressed as % of transfected cells. Data are derived from at least 200 scored cells for each coverslip. Several coverslips were analyzed from three independent experiments. Inset in (e) shows the immunoblot of lysate proteins from cells transfected with control (none) and human p27 (wt or S10A) encoding plasmids. Lysate proteins were collected at the end of the experiment, and blotted with the antibodies against the indicated proteins. In (b, c and e), means and S.E.M. are shown

Posttranslational modifications regulate p27 levels.16 Ser10 is one of the major phosphorylation sites of p27.17, 18 Challenging of quiescent NIH3T3 cells with 10 nM R1881 triggers p27 Ser10 phosphorylation, with a peak after 30 min, and slightly affects Thr187 phosphorylation in time-course experiments (Figure 2d). Quantitative analysis from three different experiments (Supplementary Figures 3S, C) shows a significant and rapid increase (about 3.5-fold within 30 min) of p27 Ser10 phosphorylation in 10 nM R1881-stimulated cells.

Ser10 phosphorylation stabilizes p27 in G0.19, 20 Thus, we hypothesized that p27 Ser10 phosphorylation impairs the movement from G0 to G1-S in cells treated with 10 nM R1881. We therefore transiently transfected NIH3T3 fibroblasts with an empty plasmid or with a plasmid encoding for the human wild-type p27 (wt p27) or a mutant of p27 carrying a substitution of Ser10 with Ala (S10A p27).17 Both versions of p27 (wt or S10A) are overexpressed (inset in Figure 2e), with the human p27 (wt or S10A) migrating more slowly than endogenous mouse p27.17 Stimulation with 10 nM R1881 significantly increases BrdU incorporation in cells overexpressing the mutant S10A p27 (right panel in Figure 2e), as compared with cells overexpressing the wt p27 (central panel in Figure 2e) or the empty (left panel in Figure 2e) plasmid. Simultaneous analysis of p27 localization shows that, irrespective of transfected plasmids, p27 is localized in the nuclei of cells treated for different times (from 0 to 12 h) with 10 nM R1881 (Figures 3a and b), indicating that Ser10 phosphorylation has a negligible effect on localization of p27. Some of the nuclei expressing p27S10A are less bright (Figure 3a), likely because of the p27 mutant degradation.

Figure 3.

Figure 3

Open in a new tab

Effect of 10 nM R1881 on localization and half-life of p27 in NIH3T3 cells. NIH3T3 cells were transfected with HA-tagged wt or S10A p27. Cells were made quiescent and then left unstimulated or stimulated for the indicated times with 10 nM R1881. In (a and b), overexpressed p27 was visualized by IF as described in Methods. Panel (a) shows representative images from one experiment in (b). Bar, 10 μM. Graphs in (b) show the quantitative score of nuclear p27, wt or S10A, overexpressed in NIH3T3 cells. Several coverslips were analyzed for each experiment, with a score of at least 100 cells for each coverslip. Means and S.E.M. are shown. In (c and d), NIH3T3 cells were transfected with HA-tagged wt p27 or S10A p27 plasmids. Cells were made quiescent and cycloheximide (50 μg/ml) was added for the last 8 h. Cells were then left unstimulated or stimulated for the indicated times with 10 nM R1881. The immunoblot of lysate proteins from cells transfected with wt p27 or S10A p27 encoding plasmids is shown in (c). The level of transfected p27 normalized to CDK-4 from two different experiments is shown in (d)

Therefore, we evaluated the half-life of overexpressed p27, wt or S10A in cycloheximide-treated NIH3T3 cells. Cells were challenged with 10 nM R1881 for the indicated times. Immunoblot and quantitative analysis show that S10A p27 undergoes a rapid and robust degradation upon R1881 stimulation. In contrast, the levels of wt p27 are stable (Figures 3c and d). Cell cycle analysis by fluorescence-activated cell sorting shows that a large number of 10 nM R1881-treated NIH3T3 fibroblasts are in G0/G1 (Supplementary Figures 4S A). Thus, 10 nM R1881 triggers p27 Ser 10 phosphorylation, stabilizes p27 and maintains cell quiescence.

Ten nanomolar R1881 activates DYRK 1B through Rac1

Dual-specificity tyrosine-phosphorylation-regulated kinases (DYRKs) control proliferation and differentiation through the phosphorylation of cell cycle regulators.21 A member of the DYRK family kinases, DYRK 1B, induces reversible G0 arrest by stabilizing p27 through Ser10 phosphorylation.19 In NIH3T3 cells, there are congruent effects on DNA synthesis, as 10 nM R1881 increases p27 Ser10 phosphorylation, whereas 1 pM R1881 reduces this phosphorylation below the basal level in lysates (Figure 4a). At the same time, 10 nM R1881 increases the activity of DYRK 1B (B). In the same experiment, a weak, but not significant, increase in DNA synthesis was detected in 10 nM R1881-treated NIH3T3 cells (A). In contrast, 1 pM R1881 concentration leaves unaffected DYRK 1B activity (panel B) and robustly increases DNA synthesis (A). No increase in DYRK 1B activity is detected in cell lysates immunoprecipitated with control antibody (Figure 4b). Quantitative analysis from different experiments shows that myelin basic protein phosphorylation by immunoprecipitated DYRK 1B increased by about fivefold upon 10 nM R1881 stimulation of quiescent cells (legend to Figure 4). Thus, hormonal activation of DYRK 1B would result in P-p27-Ser10 phosphorylation and cell quiescence.

Figure 4.

Figure 4

Open in a new tab

Ten nanomolar androgen activation of DYRK 1B induces quiescence through p27 Ser10 phosphorylation and is Rac-dependent. NIH3T3 cells were used. In (a), quiescent cells were untreated or treated for 30 min with 10 nM or 1 pM R1881. Lysate proteins were analyzed by western blot, using antibodies against the indicated proteins (lysates). The lowest section shows the corresponding BrdU incorporation analyzed by IF and expressed as % of cells. Means and S.E.M. are shown. In (b), quiescent cells were untreated or treated for 30 min with 10 nM or 1 pM R1881. Lysate proteins were immunoprecipitated with control (ctrl) or anti-DYRK 1B antibody. Immune complexes were analyzed for DYRK 1B activity using myelin basic protein (MBP) as a substrate. DYRK 1B levels in immune complexes were detected by immunoblot with anti-DYRK 1B antibody. Quantitative analysis of 10 nM R1881-triggered DYRK 1B activity from three different experiments was analyzed using the NIH Image J program. It showed a fivefold increase in kinase activity. In contrast, no significant increase in kinase activity was detected in cells stimulated with 1 pM R1881. In (c), growing cells were transfected with non-targeting siRNA (ctrl siRNA) or DYRK 1B siRNA (DYRK 1B siRNA). Cells were co-transfected with negative control siRNA Alexa-Fluor 488 to help identification of transfected cells. After transfection, cells were made quiescent, then left unstimulated or stimulated for 18 h with 10 nM R1881. After in vivo pulse with BrdU, BrdU incorporation was analyzed by IF and expressed as % of transfected cells. Data are derived from at least 300 scored cells for each experiment. Means and S.E.M. are shown. Lysate proteins from cells transfected with non-targeting (ctrl) or targeting (DYRK 1B) siRNA were analyzed by western blot with anti-DYRK 1B antibody (left panel in d), and filter was re-probed with anti-tubulin antibody, as a loading control (tub). DYRK 1B was immunoprecipitated from the same lysate proteins and its activity in immune complexes was assayed using MBP as a substrate (right panel in d). In (e), quiescent cells were left untreated or treated for 30 min with 10 nM R1881, in the absence or presence of the DYRK 1B inhibitor AZ191, which was added (1 μM) 15 min before hormonal stimulation. Control cells in right panel were treated with the inhibitor alone. In left panels, lysate proteins were immunoprecipitated with anti-DYRK 1B antibody. Immune complexes were analyzed for DYRK 1B activity using MBP as a substrate. DYRK 1B levels in immune complexes were detected by immunoblot with anti-DYRK 1B antibody. In right panels, lysate proteins were analyzed by western blot, using antibodies against the indicated proteins. In (f), quiescent cells were left untreated or treated for the indicated times with 10 nM R1881, in the absence or presence of the Rac inhibitor EHT1864 (at 10 μM), which was added 2 h before hormonal stimulation. Rac pull-down assay was performed and the amounts of total Rac and Rac-GTP were detected by western blot. In (g), quiescent cells were untreated or treated for 10 min with 1 pM or 10 nM R1881. Rac pull-down assay was performed as in (f). In (h), quiescent cells were untreated or treated for 30 min with 10 nM R1881 in the absence or presence of EHT1864 (10 μM). Lysate proteins containing the same amount of DYRK 1B (loading) were incubated with anti-DYRK 1B antibody. The lower section shows DYRK 1B activity in immune complexes, assayed using MBP as a substrate. The upper section shows the western blot of immune complexes with anti-DYRK 1B antibody

Depleting the cells of DYRK 1B increased BrdU incorporation in 10 nM R1881-treated cells (right panel in Figure 4c). BrdU incorporation in 10 nM R1881-treated control cells, expressing non-targeting siRNA, was similar to the basal level (left panel in Figure 4c). Knockdown of DYRK 1B was verified by the decrease in protein levels (left section in Figure 4d) and DYRK 1B activity (right section in Figure 4d). The DYRK 1B inhibitor AZ19122 almost completely blocks both androgen-triggered DYRK 1B activity (left panel in Figure 4e) and p27 Ser10 phosphorylation (right panel in Figure 4e), supporting the role of the kinase in this phosphorylation.

Small GTP-binding proteins control DYRK 1B.23 Ten nanomolar R1881 (Figures 4f and g), but not 1pM R1881 (Figure 4g), activates Rac1, and the Rac inhibitor EHT186424 prevents R1881-triggered activation of Rac1 (Figure 4f) and DYRK 1B (Figure 4h).

In sum, Rac-dependent activation of DYRK 1B triggers p27 Ser10 phosphorylation and induces quiescence in 10 nM R118-treated cells.

Androgen-activated Rac1 inhibits DNA synthesis and stimulates migration in fibroblasts and fibrosarcoma HT1080 cells

In 10 nM R1881-treated NIH3T3 fibroblasts, EHT1864 increases DNA synthesis (Figure 5a) and inhibits p27 Ser10 phosphorylation (Figure 5b) as well as cell motility (Supplementary Figures 4S B). In cells treated with 10 nM R1881, Rac1 knockdown (inset in Figure 5c) enables BrdU incorporation, which is unaffected by non-targeting siRNA (Figure 5c). Similarly, EHT1864 increases BrdU incorporation (Figure 5d) and inhibits migration (Supplementary Figures 4S C) in 10 nM R1881-treated HT1080 cells.

Figure 5.

Figure 5

Open in a new tab

Rac inhibition triggers DNA synthesis and suppresses p27 Ser10 phosphorylation in NIH3T3 fibroblasts and human fibrosarcoma HT1080 cells treated with 10 nM R1881. In (a–c), NIH3T3 cells were used. In (a), quiescent cells on coverslips were left untreated or treated for 18 h with 10 nM R1881 in the absence or presence of EHT1864 (10 μM). Control cells were treated with EHT1864 alone. After in vivo pulse, BrdU incorporation was analyzed by IF and expressed as % of cells. In (b), quiescent cells were left untreated or treated for 30 min with 10 nM R1881 in the absence or presence of EHT1864 (10 μM). Control cells were treated with EHT1864 alone. Lysate proteins were analyzed by western blot, using antibodies against the indicated proteins. In (c), growing cells were transfected with non-targeting siRNA (ctrl siRNA) or Rac1 siRNA (Rac1 siRNA). Cells were co-transfected with negative control siRNA Alexa-Fluor 488 to help identification of transfected cells. After transfection, the cells were made quiescent and then left unstimulated or stimulated for 18 h with 10 nM R1881. After in vivo pulse, BrdU incorporation was analyzed by IF and expressed as % of transfected cells. Data are derived from at least 500 scored cells for each experiment. Inset in (c) shows the western blot with anti-Rac antibody of lysate proteins from cells transfected with Rac1 or non-targeting (ctrl) siRNA. The filter was re-probed with anti-tubulin antibody as a loading control (tub). In (d), quiescent HT1080 cells on coverslips were left untreated or treated for 18 h with 10 nM R1881 in the absence or presence of EHT1864 (10 μM). Control cells were treated with EHT1864 alone. BrdU incorporation was analyzed as in (a). Means and S.E.M. are shown

In conclusion, Rac1 activation attenuates mitogenic signalling through DYRK 1B and p27 Ser10 phosphorylation, whereas it stimulates migration in 10 nM-stimulated fibroblasts and fibrosarcoma cells.

AR/FlnA association halts DNA synthesis in androgen-treated fibroblasts

The androgen-triggered AR/FlnA complex controls Rac1 activation and motility in NIH3T3 fibroblasts.6 Aiming to dissect the role of this complex in regulating NIH3T3 cell proliferation, we initially looked at the effects of the overexpression of an AR mutant (Δ622-670 hAR)25 that does not associate with FlnA and inhibits cell motility in 10 nM R1881-treated NIH3T3 cells.6

The AR mutant does not mediate R1881-induced activation of DYRK 1B (Figure 6a) or Rac (Figure 6b), indicating that the AR/FlnA complex controls androgen-triggered Rac/DYRK 1B activation. Ten nanomolar R1881 challenging of cells expressing the wt hAR or the empty pSG5 control plasmid increased Rac activation (Figure 6b), which was abolished by EHT1080. Overexpression of the Δ622-670 hAR mutant increases proliferation (Figure 6c), whereas it inhibits migration in 10 nM R1881-treated NIH3T3 cells (Figure 6d).

Figure 6.

Figure 6

Open in a new tab

An AR mutant unable to interact with FlnA induces the proliferative phenotype and impairs motility of NIH3T3 cells challenged with 10 nM R1881. In (a and b), NIH3T3 cells were transfected with wild-type hAR (AR wt) or its mutant (622–670 hAR; ΔAR), or the empty pSG5 (ctrl) plasmid. Cells were made quiescent and then left untreated or treated for 30 min (a) or the indicated times (b) with 10 nM R1881. When indicated, EHT1864 was added at 10 μM. In (a), AR (wt or ΔAR) and DYRK 1B were detected by western blot of lysate proteins using the appropriate antibodies (loading in upper panel). Lysate proteins were immunoprecipitated using anti-DYRK 1B antibody, and DYRK 1B activity was assayed using MBP as a substrate (lower panel). In (b), Rac pull-down assay was performed and the amount of Rac or Rac-GTP was detected by western blot. In (c and d), NIH3T3 cells were transfected with the empty (ctrl) or ΔAR- (ΔAR) encoding plasmid. pEGFP plasmid (at 0.2 μg; Clontech) was included to help identification of transfected cells. Transfected cells were made quiescent. In (c), cells were left unstimulated or stimulated for 18 h with 10 nM R1881. After in vivo pulse, BrdU incorporation was analyzed by IF and expressed as % of transfected cells. In (d), cells were left unstimulated or stimulated for 6 h with 10 nM R1881. Migrated cells were scored and data expressed as relative increase. In (c and d), data are derived from at least 500 scored cells for each experiment. Means and S.E.M. are shown

As the hAR mutant lacks a large amino acid sequence, we synthesized a small peptide derived from the AR 622-670 amino acid sequence responsible for interaction of the receptor with FlnA.25 A hydrocarbon-stapled version of this peptide was also synthesized in which residues Ala628 and Lys632 were each replaced with an olefinic amino acid that allows them to be cross-linked. This cross-link locks the peptide into an alpha-helical conformation, as this sequence is predicted to form an alpha helix. The stapled version should have increased activity. In fact, stapled peptides have increased cell permeability, higher affinity for the target, and decreased degradation as compared to their unstapled counterpart.26 The amino acid sequence of the stapled peptide (S) is shown in Supplementary Figure 5S. The S peptide displaces the 10 nM R1881-induced AR/FlnA complex assembly in NIH3T3 cells (Figure 7a) and inhibits p27 Ser10 phosphorylation (Figure 7b). Again, it increases DNA synthesis (Figure 7c) and inhibits cell motility (Figure 7d) triggered by 10 nM R1881 in NIH3T3 cells. Furthermore, the S peptide does not affect serum-induced DNA synthesis or motility in NIH3T3 cells, and does not interfere with serum-induced DNA synthesis and motility in AR-negative human prostate cancer DU-145 cells (Supplementary Figures 5S, A–D). Thus, the S peptide specifically acts in androgen-stimulated AR-expressing cells. Finally, the S peptide does not disrupt the well-known association between FlnA and integrin β1 27 in NIH3T3 cells (Supplementary Figure 5S E) and leaves unaffected AR-mediated transcriptional activity in NIH3T3, LNCaP and HT1080 cells (Supplementary Figure 5S F).

Figure 7.

Figure 7

Open in a new tab

The AR/FlnA complex induces p27 Ser10 phosphorylation, stimulates migration and halts DNA synthesis in NIH3T3 cells treated with 10 nM R1881. In (a), quiescent NIH3T3 cells were left untreated or treated for 5 min with 10 nM R1881, in the absence or presence of the indicated concentrations of S peptide (1 or 10 nM). The peptide was added 30 min before hormonal stimulation. Lysates were incubated with anti-AR antibody and proteins in immune complexes were blotted with antibodies against the indicated proteins. In (b), quiescent cells on coverslips were left untreated or treated for 18 h with 10 nM R1881 in the absence or presence of the indicated concentration of S peptide. After in vivo pulse, BrdU incorporation was analyzed as above. In (c), quiescent cells were left untreated or treated with 10 nM R1881 in the absence or presence of the indicated concentrations of S peptide. Cells were allowed to migrate in trans-well chambers and migrated cells were scored by fluorescent microscopy. Data were expressed as relative increase. In (d), quiescent NIH3T3 cells were left untreated or treated for 30 min with 10 nM R1881, in the absence or presence of 10 nM S peptide. Control cells were treated with 10 nM S peptide alone. Lysate proteins were immune-blotted with antibodies against the indicated proteins. In (e and f), growing cells were transfected with non-targeting (ctrl siRNA) or FlnA (FlnA siRNA) siRNA. Cells were co-transfected with negative control siRNA Alexa-Fluor 488 to help identification of transfected cells. In (e), the western blot of lysate proteins from cells transfected with non-targeting (ctrl siRNA) or targeting (FlnA siRNA) siRNA with anti-FlnA antibody is shown. The filter was re-probed with anti-tubulin antibody as the loading control (tub). In (f), cells transfected with ctrl siRNA or FlnA siRNA were made quiescent and then left unstimulated or stimulated for 18 h with 10 nM R1881. After in vivo pulse, BrdU incorporation was analyzed by IF and expressed as % of transfected cells. In (g), cells transfected with ctrl siRNA or FlnA siRNA were made quiescent and then left unstimulated or stimulated with 10 nM R1881. Migrated cells were scored and data expressed as relative increase. In (b, c, f and g), data are derived from at least 500 scored cells for each experiment. Means and S.E.M. are shown

Depleting NIH3T3 cells of FlnA (Figure 7e) increases DNA synthesis (Figure 7f) and inhibits migration (Figure 7g) triggered by 10 nM R1881.

In conclusion, data in Figures 6 and 7 indicate that the AR/FlnA complex simultaneously halts cell cycle and promotes migration in cells challenged with physiological androgen concentration through its action on Rac. Interfering in this complex restores the proliferative phenotype, whereas impairing the migratory phenotype of fibroblasts.

Androgens counteract Ras-induced transformation

Ras- and Src-transformed NIH3T3 fibroblasts harbor AR (Supplementary Figure 2S B).5 We therefore analyzed the ability of androgens to reduce fibroblast transformation induced by the oncogenic form of Src (Src527F)28 or Ras (V12Ras).29 Albeit to a different extent, the activated forms of Src and Ras transform NIH3T3 fibroblasts in a focus assay (Figures 8a and b). Ten nanomolar R1881 drastically reduces transformation by Ras, leaving Src-induced transformation unaffected (Figures 8a and b). Again, 10 nM R1881 inhibits BrdU incorporation in Ras- but not in Src-transformed fibroblasts (Figure 8c), and triggers rapid (15 min) and persistent (8 h) p27 Ser10 phosphorylation in Ras-transformed cells. In contrast, p27 Thr187 phosphorylation peaks at 30 min and then decreases (Figure 8d). The sustained p27 Ser10 phosphorylation we observe in different experiments (Supplementary Figures 6S A) is likely due to DYRK 1B hyperactivation in Ras-transformed cells.30 Thus, the rapid and persistent p27 Ser10 phosphorylation induced by androgens in Ras-transformed fibroblasts overcomes the effect of p27 Thr187 phosphorylation with consequent p27 degradation,31 and might be responsible for the inhibitory action of androgen. Oncogenic Src likely escapes the androgen effect through alternative nuclear effectors (e.g., Myc)28 to those used by Ras in transforming cells.

Figure 8.

Figure 8

Open in a new tab

Androgen inhibits Ras- but not Src-induced transformation. In (a and b), NIH3T3 cells were transfected with the indicated expression plasmids or the empty plasmid (ctrl) and cultured in the absence or presence of 10 nM R1881 as reported in Methods. After 12 days, the cells were stained with 0.5% crystal violet and the number of foci was counted. In (a), mean values from three independent experiments, each conducted in duplicate, are shown in the graph, representing the percentages of transformed foci relative to Src527F or RasV12 plasmids. The standard error for each value is shown. n represents the number of experiments. In (b), representative plates from a single experiment conducted in duplicate are shown. Growing Src- or Ras-transformed NIH3T3 cells were used. In (c), cells on coverslips were maintained for 3 days in 0.5% dextran-coated charcoal-stripped serum and then left unstimulated or stimulated for 18 h with 10 nM R1881. After in vivo pulse, BrdU incorporation was analyzed as above. Data are derived from at least 800 scored cells for each experiment. Means and S.E.M. are shown. n represents the number of experiments. In (d), Ras-transformed cells were maintained for 3 days in 0.5% dextran-coated charcoal-stripped serum and then left unstimulated or stimulated for the indicated times with 10 nM R1881. Lysate proteins were analyzed using the anti-P-Ser10 or P-Thr197 p27. Filters were re-probed with p27 or anti-tubulin (tub) Ab, as the loading control

Discussion

We here investigated the role of AR in proliferation of mesenchymal and transformed mesenchymal cells. Ten nanomolar R1881 or DHT fails to induce DNA synthesis in primary or immortalized untransformed fibroblasts and human fibrosarcoma HT1080 cells. The anti-androgen Bic (Casodex) allows DNA synthesis and proliferation, indicating the involvement of AR in these proliferative responses to the antagonist. It should be noted that Bic, frequently used in human PCa androgen deprivation therapy, often promotes PCa progression.1 Our findings indicate that Bic induces undesired signals in mesenchymal cells.

Androgens stimulate fibroblast DNA synthesis at very low (picomolar) concentration, and cell motility at higher (nanomolar) concentration.5, 6 Thus, mesenchymal cells can switch from a proliferative to a migratory phenotype when androgen concentration increases. The migratory effect exerted by androgens could play a role in different physiological and pathological conditions, including male sexual differentiation, when presumptive peritubular myoid cells migrate into the testis from mesonephros. At this stage, peritubular myoid cells strongly reduce their proliferation rate and begin to consistently express AR during their inward migration.32 In adults, such a switch might locally occur during wound healing or cancer progression.

We analyzed the mechanism underlying the molecular switch from proliferative to migratory action of androgens. The mode of action of androgens does not depend on the dichotomous androgen effect on AR-mediated transcription or AR nuclear translocation, as shown in Supplementary data (Supplementary Figure 6S).5 AR is, indeed, permanently poised in the extra-nuclear compartment of NIH3T3 and HT1080 cells, where it recruits different effectors or scaffolds leading to different biological outcomes. At low androgen levels, AR recruits Src and the regulatory subunit of PI3-K, and activates Erk and Akt (Supplementary Figure 6S),5 thereby fostering proliferation. In contrast, at high androgen levels, AR recruits FlnA and cell migration follows.6 Upon 10 nM androgen-triggered AR/FlnA complex assembly, FlnA acts as a scaffold for the spatial organization of the Rac-mediated signalling pathway, enabling the recruitment by Rac of specific effectors (e.g., DYRK 1B) involved in cell quiescence.

In addition to stimulating proliferation, Rho protein family members might inhibit cell cycle.33 Rho E behaves as an onco-suppressor gene in PCa34 and halts cell cycle in serum-stimulated NIH3T3 fibroblasts.35 We here report that AR-mediated cell cycle inhibition depends on the activation of Rac 1 and its dependent pathway in fibroblasts and HT1080 cells. DYRK 1B is controlled by Rac-activated MKK3 and induces NIH3T3 cell quiescence.19 We have consistently observed that 10 nM R1881 triggers Rac activity, which controls DYRK 1B in NIH3T3 cells. Experiments with inhibitors of Rac1 and DYRK 1B strengthen the role of these effectors in androgen-driven p27 Ser10 phosphorylation. Neither Rac nor DYRK 1B activation is detected in NIH3T3 cells treated with low (1 pM) androgen concentration, which triggers the proliferative phenotype. Silencing and chemical inhibition of DYRK 1B allows DNA synthesis, further supporting the role of this enzyme in the quiescent state of 10 nM R1881-treated NIH3T3 fibroblasts. The observed effect by EHT1864 or Rac silencing links androgen-triggered Rac activation with DYRK 1B activity and cell quiescence. In sum, the 10 nM androgen-triggered FlnA/Rac/DYRK 1B pathway halts cell cycle through p27 Ser10 phosphorylation and might also lead to the inhibition of transformation induced by oncogenic Ras, but not oncogenic Src in these cells. Thus, AR could act as a growth suppressor by specifically inhibiting Ras-driven pathways, without interfering in the proliferation elicited by different signalling mechanisms. DYRK 1B is an active kinase in pancreatic, ovarian and colon cancer cells, and controls hedgehog signalling in the stromal compartment of mouse model of pancreatic cancer.36 Oncogenic Ras activates DYRK 1B through the Rac1/MKK3 signalling pathway, indicating that DYRK 1B acts as a regulator in Ras-driven transformation and tumor progression.30, 36, 37 Notably, DYRK 1B inhibition enables the growth of stromal cells in a genetic model of pancreatic cancer, likely through hedgehog signalling.37 By increasing fibroblast growth and stromal collagen content, DYRK 1B inhibition might restrain tumor growth in vivo.

Ras oncogenic mutations have been described in a large number of cancers, including pancreatic (90%), colon (50%), lung (30%) and thyroid tumors (50%) as well as myeloid leukemia (30%).38 Pancreatic, colon and lung cancers express AR.39, 40 Proliferation of various AR-expressing pancreatic cancer cells is insensitive to DHT,41 and androgens inhibit colon tumor survival through a putative membrane AR.42 The growth of small-cell lung carcinoma H1184 cell line is sensitive to low, but not high, DHT concentrations, and the growth of non-small-cell lung carcinoma H1993 cell line is inhibited by DHT.39 We observe that the proliferation of human fibrosarcoma HT1080 cells, exhibiting an activated N-Ras,13 is insensitive to 10 nM androgen. Thus, androgens might elicit anti-proliferative signals in human cancers bearing Ras oncogenic mutations. Altogether, these findings indicate that further exploration of the androgen/AR axis should be pursued in stromal and epithelial compartment of these cancers. Lastly, the stapled peptide used in this study, as well as other small molecules capable of disrupting the AR/FlnA interaction, might represent a promising approach to specifically modulate AR functions in stromal tissue and rescue hormone proliferative responsiveness in human prostate cancers.

Materials and Methods

Chemical reagents

TentaGel R RAM resin was obtained from Peptide International Inc. (Louisville, KY, USA). N-alpha-Fmoc-protected amino acids were purchased from Novabiochem (San Diego, CA, USA). The N-alpha-Fmoc-protected unusual olefinic amino acid (S)-2-(((9H-fluoren-9-yl) methoxy)carbonyl-amino)-2-methyl-hept-6-enoic acid (Fmoc-S5-OH) was used for synthesis of the stapled peptide. Solvents and coupling reagents, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and 1-hydroxybenzotriazole were obtained from Sigma-Aldrich (Milwaukee, WI, USA) and American Bioanalytical (Natick, MA, USA). The Rac inhibitor EHT1846 was from Sigma. The DYRK 1B inhibitor AZ191 was from Selleckchem (Houston, TX, USA).

Constructs

The wt hAR was in pSG5 43 and the mutant Δ622-670 hAR was in psV1.25 The kinase-active Src (Src527F)28 and the active form of Ras (Ras V12)29 were used. The HA-tagged wt p27 and the mutant Ser10Ala p27 in pcDNA317 were a gift from M. Pagano (Department of Pathology, NYU Cancer Institute, University School of Medicine and Howard Hughes Medical Institute, NY, USA). The human full-length p27 promoter (pGL2-p27-Luc) was a gift from P. Coffer (Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands). The 3416 construct, containing four copies of the wt slp-HRE2 (5′-TGGTCAgccAGTTCT-3′) and the 3424 construct (5′-TGGACAgccAGTTCT-3′), were cloned in the NheI site in pTK-TATA-Luc.44

Cell culture, transfection, transactivation assay and siRNA

Src- and Ras-transformed NIH3T3 fibroblasts were a gift from M.V. Barone (Department of Translational Medical Science and European Laboratory for the Investigation of Food Induced Disease, University of Naples Federico II, Naples, Italy). They were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin (Pen/Strepto) and glutamine (2 mM), and maintained at 37 °C in humidified 5% CO2 atmosphere. Twenty-four hours before androgen stimulation, cell medium was replaced with phenol red-free DMEM containing Pen/Strepto and supplemented with 0.1% charcoal-stripped serum. Karyotypically heterogeneous human fibrosarcoma HT1080 cells45 were a gift from P. Friedl (Department of Cell Biology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands). HT1080 cells, early-passage NIH3T3 cells, MEFs and MFs were cultured in DMEM supplemented with 10% FCS, Pen/Strepto, glutamine (2 mM), and maintained at 37 °C in humidified 5% CO2 atmosphere. Unless otherwise stated, NIH3T3, MEF, MF and HT1080 cells were made quiescent using phenol red-free DMEM supplemented with Pen/Strepto, glutamine (2 mM) and 0.1% charcoal-stripped FCS for 24 h. Prostate cancer-derived fast-growing LNCaP and DU-145 cells were from ATCC (Manassas, VA, USA). They were cultured in RPMI1640 supplemented with 5% (LNCaP) or 10% (DU-145) FCS and Pen/Strepto, and maintained at 37 °C in humidified 5% CO2 atmosphere. After reaching sub-confluence, growing LNCaP cells were kept in phenol red-free RPMI1640 medium containing 5% charcoal-stripped calf serum and Pen/Strepto for 3 days and then used. Growing DU-145 cells were kept in phenol red-free RPMI1640 containing Pen/Strepto and glutamine (2 mM) in the absence of serum for 24 h and then used. Purified wt or ΔAR mutant encoding plasmids were transfected at 1 μg in sub-confluent NIH3T3 cells, using the Superfect reagent (QIAGEN GmbH, Hilden, Germany). Twenty-four hours later, transfected cells were made quiescent and used. For ARE-luc reporter assay, NIH3T3 cells (at 70% confluence) in phenol red-free DMEM containing 10% charcoal-stripped serum were used. Cells were transfected by Superfect with 1 μg of 3416-pTK-TATA-Luc or 3424-pTK-TATA-Luc constructs, alone or with 0.5 μg pSG5-hAR-expressing plasmid. Ten hours later, transfected cells were made quiescent for 24 h and then left unstimulated or stimulated with 1 pM or 10 nM R1881 (Perkin Elmer, Waltham, MA, USA) for 18 h. The purified human p27 promoter was transfected (at 1 μg) using Superfect in sub-confluent NIH3T3 cells in phenol red-free DMEM containing 10% serum. Twelve hours later, transfected cells were made quiescent and then left unstimulated or stimulated with 1 pM or 10 nM R1881 (Perkin Elmer) or 20% serum for 10 h. Luciferase activity from cell lysates was measured using a luciferase assay system (Promega Corporation, Madison, WI, USA) and values were corrected using CH110-expressed-β-galactosidase activity (GE Healthcare, Little Chalfont, UK). The purified human HA-tagged p27 (wt or S10A) was transfected (at 0.5 μg) using Superfect in sub-confluent NIH3T3 cells cultured in DMEM containing 10% serum. Ten hours later, transfected cells were made quiescent for 36 h and then left unstimulated or stimulated. When indicated, cycloheximide (Sigma) was added (at 50 μg/ml) 8 h before hormonal stimulation. FlnA siRNA was performed using a three target-specific 20–25 nt siRNA pool (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Rac1 siRNA was performed using a four target-specific 20–25 nt siRNA pool (Santa Cruz). Non-targeting siRNAs, containing a scrambled sequence, were from Santa Cruz. DYRK 1B siRNA was performed using double-stranded Stealth DYRK 1B siRNA (Explera, Jesi, Italy). Non-targeting siRNA was from Explera. siRNAs were transfected using Lipofectamine 2000 (Gibco, Monza, Italy) in growing NIH3T3 cells in Optimem/DMEM (50% v/v) containing 10% serum. Transfection medium was discarded 10 h later and cells were washed twice using phenol red-free DMEM. Transfected cells were then made quiescent for 36 h and used.

Migration, DNA synthesis, MTT analysis, fluorescence-activated cell sorting analysis and transformation assay

Trans-well assay was performed using collagen (type I from rat-tail at 100 mg/ml; BD Biosciences, San Jose, CA, USA)-coated Trans-well chamber system with 8 μm pore polycarbonate membrane (Nunc, Thermo Fisher Scientific Inc., Waltham, MA, USA). NIH3T3 cells were plated in the upper chamber at 2 × 104 per well in 200 μl of phenol red-free DMEM containing 0.5% bovine serum albumin. In FlnA siRNA experiments, NIH3T3 cells were co-transfected with siRNA Alexa Fluor 488 to help identify the transfected cells. Cells were allowed to migrate for 6 h in a humidified chamber at 37 °C with 5% CO2 in the absence or presence of the indicated compounds. Cells on the upper side were then detached. NIH3T3 fibroblasts on the underside were fixed in 4% paraformaldehyde (Sigma) for 15 min and stained with Hoechst 33258 (Sigma) for 10 min. Alexa Fluor 488-transfected NIH3T3 fibroblasts were fixed in 4% paraformaldehyde for 15 min. Cells were finally counted with a DMBL (Leica, Wetzlar, Germany) fluorescent microscope using HCPL Fluotar × 20 objective in 10 random microscopic fields. DNA synthesis was evaluated by analysing BrdU incorporation. After in vivo pulse with 100 μM (final concentration) BrdU (Sigma), BrdU incorporation was analyzed by immunofluorescence (IF), as reported.5 MTT assay was performed as described.46 For fluorescence-activated cell sorting analysis, quiescent NIH3T3 cells (2.0 × 105 for each experimental point) were left untreated or treated for the indicated times with 10 nM R1881. Cells were collected, resuspended in 500 μl of a buffer containing 0.1% NP-40, 0.1% sodium citrate, 50 μg/ml propidium iodide, 1 mg/ml RNAse A and 0.1 mM EDTA. Cells were then incubated in the dark for 30 min and samples were measured by a FACS Calibur flow cytometer using Cell Quest software (Becton Dickinson, BD Biosciences). Results from three different experiments were analyzed using Cell Quest software (Becton Dickinson) and ModFit LT version 3 Software (Verity, Topsham, ME, USA). For transformation assay, early-passage NIH3T3 cells were seeded at 1.5 × 105 cells per well in 6-well dishes the day before transfection with purified RasV12 or Src527F encoding plasmids (both at 0.5 μg). Transfection was performed using Superfect in cells cultured in DMEM containing 10% charcoal-stripped FCS, as reported.47 Two days later, the cells were transferred to 10 cm plates. After reaching confluence, they were kept in DMEM containing 5% charcoal-stripped FCS. When indicated, R1881 (10 nM) was added every day. Control plates were treated with vehicle alone (0.001% ethanol). After 12 days, the plates were stained with 0.5% crystal violet.

Immunofluorescence

Cells on coverslips were fixed and permeabilized.5 Endogenous AR in NIH3T3 cells was visualized using diluted (1 : 100 in PBS) rabbit polyclonal anti-AR antibody (Ab-2, Neo-Markers, Thermo Fisher Scientific Inc.). Rabbit antibody was detected using diluted (1 : 200 in PBS containing 0.2% bovine serum albumin) anti-rabbit fluorescein-conjugated antibodies (Jackson Laboratories, Las Vegas, NV, USA). DNA synthesis was analyzed using diluted (1 : 50 in PBS) mouse monoclonal anti-BrdU antibody (clone BU-1, GE Healthcare). Mouse antibody was detected using diluted (1 : 200 in PBS) Texas red-conjugated goat anti-mouse antibody (Jackson Laboratories). Endogenous p27 was stained using diluted (1 : 100 in PBS containing 0.1% bovine serum albumin) rabbit anti-p27 polyclonal antibody (C-19; Santa Cruz). Diluted (1 : 200 in PBS) anti-rabbit fluorescein isothiocyanate-conjugated antibody (Jackson Laboratories) was used as a secondary antibody. For localization of ectopically expressed p27, staining was performed using anti-HA (F-5; Santa Cruz) as primary antibody and FITC-conjugated anti-mouse IgG (Jackson Laboratories) as the secondary reagent. Coverslips were finally stained with Hoechst 33258, inverted and mounted in Mowiol (Calbiochem, Millipore/Merck KGaA, Darmstadt, Germany). Fields were analyzed with a DMBL Leica (Leica) fluorescent microscope using HCX PL Apo × 63 oil objective. Images were captured using DC480 camera (Leica) and acquired using FW4000 (Leica) software. Confocal microscopy analysis was performed using a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany), as reported.48 The image collection periods and exposures are identical for the different experimental conditions.

Peptide synthesis

Peptides were synthesized by 9-fluorenylmethoxycarbonyl (Fmoc)/tert-butyl solid-phase method with an Applied Biosystem (Thermo Fisher Scientific Inc.) peptide synthesizer A431. Peptides were assembled on TentaGel R RAm resin with an initial load of 0.19 mmol/g. Coupling reactions were conducted by means of the 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate-1-hydroxybenzotriazole method. N-terminal primary amines were acetylated utilizing acetic anhydride and diisopropylethylamine (DIEA). For the stapled peptide, Fmoc-S5-OH was coupled manually in threefold molar excess in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole and DIEA. The ring-closing metathesis reaction was performed on the N-terminal acetylated peptide while still on the solid support according to literature.49, 50, 51 Cleavage of peptides from the resin was achieved with a trifluoroacetic acid/water/triisopropylsilane mixture (92.5/5/2.5, v/v) for 3 h. After the resin had been removed by filtration, the filtrate was concentrated by flushing with nitrogen gas and crude peptides were precipitated with diethyl ether. Crude peptide was purified using reversed-phase high-performance liquid chromatography on a preparative C4 column (BioAdvantage Pro 300, Thomson Liquid Chromatography, Thomson Instrument Company, Oceanside, CA, USA) with a water/acetonitrile solvent system containing trifluoroacetic acid. Purified peptide was characterized by matrix-associated laser desorption ionization time-of-flight mass spectrometry (MALDI micro MX, Waters,Milford, MA, USA) and reversed-phase high-performance liquid chromatography on an analytical C18 column (Eclipse XDB-C18, Agilent Technology, Santa Clara, CA, USA). The purity of the peptides was found to be >95%.

Antibody, immunoprecipitation, immunoblotting, kinase and Rac assays

Lysates (at 2 mg/ml protein concentration) were prepared as reported.14 Rac activity from quiescent NIH3T3 was analyzed as described,5 using the Rac Activation Assay Kit (Upstate Biotechnology Inc., Lake Placid, NY, USA). AR was revealed using rabbit polyclonal anti-AR antibodies (N-20 or C19; Santa Cruz). The rabbit polyclonal anti-ERalpha antibody (543; Santa Cruz) was used to detect ERalpha. PgR was detected using the mouse monoclonal anti-PgR antibody (6A1; Cell Signaling Technology, Danvers, MA, USA). Total Akt and P-Ser 473 Akt were detected using appropriate antibodies (Cell Signaling Technology). Erk and P-Tyr 204 Erk were detected using appropriate antibodies (Santa Cruz). p27 was detected using rabbit anti-p27 polyclonal antibody (C-19; Santa Cruz; diluted 1 : 100 in PBS containing 0.1% bovine serum albumin). For CDK-4 detection, the rabbit polyclonal antibody (c-22 from Santa Cruz) was used. Rabbit polyclonal anti-phosho-p27 antibodies (P-Ser10 or P-Thr187; Zymed Laboratories, Thermo Fisher Scientific Inc.) were used to reveal P-p27. DYRK 1B was immunoprecipitated and revealed by western blot using the rabbit polyclonal anti-DYRK 1B antibody (Cell Signaling Technology). DYRK 1B activity in immune complexes was assayed as reported,52 using myelin basic protein as a substrate. The ECL system (GE Healthcare) was used to detect immunoreactive proteins.

Acknowledgments

We thank M.V. Barone for Src- and Ras-transformed fibroblasts, F. Claessens for 3416 and 3424 constructs, P. Coffer for pGL2-p27 construct, E.L. Yong for Δ622-670 hAR mutant, P. Friedl for human fibrosarcoma HT1080 cells, and M. Pagano for HA-tagged wt p27 and S10A constructs. The Italian Association for Cancer Research (IG11520 to A.M.) and the Italian Ministry of University and Scientific Research (P.R.I.N. 2010-2011; 2010NFEB9L_002 to G.C.) supported this work. Pia Giovannelli and Marzia Di Donato are supported by a fellowship of the Italian Ministry of University and Scientific Research.

Author Contributions

GC, AM and FA contributed to the concept and design of the study and writing of the paper; RH, FB and EA contributed to concept and design of the S peptide; PG, MDD and AC contributed to the design of experiments and analysis of data; PG, AC and MDD performed experiments.

Glossary

AR

androgen receptor

BrdU

bromodeoxyuridine

DHT

dihydrotestosterone

ER

estradiol receptor

ECM

extracellular matrix

IF

immunofluorescence

DYRK 1B

dual-specificity tyrosine-phosphorylation-regulated kinase 1B

MAPK

mitogen-activated protein kinase

MEK-1

mitogen-activated kinase

MKK3

MAP kinase 3

PgR

progesterone receptor

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by G Dewson

Supplementary Material

Supplementary Figure S1
Click here for additional data file. (519.9KB, tif)
Supplementary Figure S2
Click here for additional data file. (635.6KB, tif)
Supplementary Figure S3
Click here for additional data file. (661.8KB, tif)
Supplementary Figure S4
Click here for additional data file. (1.5MB, tif)
Supplementary Figure S5
Click here for additional data file. (1.5MB, tif)
Supplementary Figure S6
Click here for additional data file. (2MB, tif)
Supplementary Figure Legends
Click here for additional data file. (49.5KB, doc)

References

  1. 1Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010; 29: 3593–3604. [DOI] [PubMed] [Google Scholar]
  2. 2Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007; 6: 647–651. [DOI] [PubMed] [Google Scholar]
  3. 3Diaw L, Roth M, Schwinn DA, d'Alelio ME, Green LJ, Tangrea JA. Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention. In Vitro Cell Dev Biol Anim 2005; 41: 142–148. [DOI] [PubMed] [Google Scholar]
  4. 4Sun X, He H, Xie Z, Qian W, Zhau HE, Chung LW et al. Matched pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells. In Vitro Cell Dev Biol Anim 2010; 46: 538–546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. 5Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a non-transcriptional receptor action. J Cell Biol 2003; 161: 547–556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. 6Castoria G, D'Amato L, Ciociola A, Giovannelli P, Giraldi T, Sepe L et al. Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One 2011; 6: e17218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. 7Chen P, Gupta K, Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol 1994; 124: 547–555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. 8Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994; 127: 847–857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. 9Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163–1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. 10De Donatis A, Comito G, Buricchi F, Vinci MC, Parenti A, Caselli A et al. Proliferation versus migration in platelet-derived growth factor signaling: the key role of endocytosis. J Biol Chem 2008; 283: 19948–19956. [DOI] [PubMed] [Google Scholar]
  11. 11Ghosh P, Beas AO, Bornheimer SJ, Garcia-Marcos M, Forry EP, Johannson C et al. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell 2010; 21: 2338–2354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. 12Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A et al. Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature 2013; 499: 166–171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. 13Geiser AG, Anderson MJ, Stanbridge EJ. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated Ras oncogenes. Cancer Res 1989; 49: 1572–1577. [PubMed] [Google Scholar]
  14. 14Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M et al. Steroid-induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19: 5406–5417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. 15Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18: 2699–2711. [DOI] [PubMed] [Google Scholar]
  16. 16Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 1861–1864. [DOI] [PubMed] [Google Scholar]
  17. 17Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20: 6672–6682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. 18Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002; 277: 14355–14358. [DOI] [PubMed] [Google Scholar]
  19. 19Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004; 279: 22498–22504. [DOI] [PubMed] [Google Scholar]
  20. 20Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006; 20: 47–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. 21Becker W. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 2012; 11: 3389–3394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. 22Ashford AL, Oxley D, Kettle J, Hudson K, Guichard S, Cook SJ et al. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem J 2014; 457: 43–56. [DOI] [PubMed] [Google Scholar]
  23. 23Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003; 278: 41347–41354. [DOI] [PubMed] [Google Scholar]
  24. 24Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem 2007; 282: 35666–35678. [DOI] [PubMed] [Google Scholar]
  25. 25Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA 2003; 100: 4562–4567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. 26Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol 2012; 503: 3–33. [DOI] [PubMed] [Google Scholar]
  27. 27Loo DT, Kanner SB, Aruffo A. Filamin binds to the cytoplasmic domain of the beta 1 integrin: identification of aminoacids responsible of this interaction. J Biol Chem 1998; 273: 23304–23312. [DOI] [PubMed] [Google Scholar]
  28. 28Barone MV, Courtneidge SA. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 1995; 378: 509–512. [DOI] [PubMed] [Google Scholar]
  29. 29Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89: 457–467. [DOI] [PubMed] [Google Scholar]
  30. 30Jin K, Park S, Ewton DZ, Friedman E. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. Cancer Res 2007; 1: 7247–7255. [DOI] [PubMed] [Google Scholar]
  31. 31Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464–1478. [DOI] [PubMed] [Google Scholar]
  32. 32Sharpe RM. Pathways of endocrine disruption during male sexual differentiation and masculinization. Best Pract Res Clin Endocrinol Metab 2006; 20: 91–110. [DOI] [PubMed] [Google Scholar]
  33. 33Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690–701. [DOI] [PubMed] [Google Scholar]
  34. 34Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schäfer G et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005; 64: 332–340. [DOI] [PubMed] [Google Scholar]
  35. 35Villalonga P, Guasch RM, Riento K, Ridley AJ. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 2004; 24: 7829–7840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. 36Lauth M, Bergström A, Shimokawa T, Tostar U, Jin Q, Fendrich V et al. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol 2010; 17: 718–725. [DOI] [PubMed] [Google Scholar]
  37. 37Deng X, Friedman E. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells. Genes Cancer 2014; 5: 9–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. 38Bos J L. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–4689. [PubMed] [Google Scholar]
  39. 39Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G et al. Research resource: diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol 2012; 26: 1443–1454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. 40Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2013; 33: 3225–3234. [DOI] [PubMed] [Google Scholar]
  41. 41Okitsu K, Kanda T, Imazeki F, Yonemitsu Y, Ray RB, Chang C et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer 2010; 1: 859–867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. 42Gu S, Papadopoulou N, Nasir O, Föller M, Alevizopoulos K, Lang F et al. Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med 2011; 17: 48–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. 43Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988; 85: 7211–7215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. 44Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W et al. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 2000; 275: 12298–12305. [DOI] [PubMed] [Google Scholar]
  45. 45Imle A, Polzer B, Alexander S, Klein CA, Friedl P. Genomic instability of micronucleated cells revealed by single-cell comparative genomic hybridization. Cytometry 2009; 75: 562–568. [DOI] [PubMed] [Google Scholar]
  46. 46Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor {alpha} tyrosine-phosphorylated peptide. Mol Cancer Res. 2007; 11: 1213–1221. [DOI] [PubMed] [Google Scholar]
  47. 47Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012; 31: 4868–4877. [DOI] [PubMed] [Google Scholar]
  48. 48Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A et al. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol 2008; 182: 327–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. 49Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129: 2456–2457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. 50Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010; 18: 411–422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. 51Bird G H, Bernal F, Pitter K, Walensky LD. Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains. Meth Enzymol 2008; 446: 369–386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. 52Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y et al. Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem 2006; 281: 38489–38497. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure S1
Click here for additional data file. (519.9KB, tif)
Supplementary Figure S2
Click here for additional data file. (635.6KB, tif)
Supplementary Figure S3
Click here for additional data file. (661.8KB, tif)
Supplementary Figure S4
Click here for additional data file. (1.5MB, tif)
Supplementary Figure S5
Click here for additional data file. (1.5MB, tif)
Supplementary Figure S6
Click here for additional data file. (2MB, tif)
Supplementary Figure Legends
Click here for additional data file. (49.5KB, doc)

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES